EA036542B9 - Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора - Google Patents
Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептораInfo
- Publication number
- EA036542B9 EA036542B9 EA201891714A EA201891714A EA036542B9 EA 036542 B9 EA036542 B9 EA 036542B9 EA 201891714 A EA201891714 A EA 201891714A EA 201891714 A EA201891714 A EA 201891714A EA 036542 B9 EA036542 B9 EA 036542B9
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- orexin receptor
- halo
- receptor modulators
- receptor activity
- substituted piperidines
- Prior art date
Links
- 108050000742 Orexin Receptor Proteins 0.000 title abstract 4
- 102000008834 Orexin receptor Human genes 0.000 title abstract 4
- 150000003053 piperidines Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662294940P | 2016-02-12 | 2016-02-12 | |
| US201662336102P | 2016-05-13 | 2016-05-13 | |
| PCT/US2017/017408 WO2017139603A1 (en) | 2016-02-12 | 2017-02-10 | Halo-substituted piperidines as orexin receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EA201891714A1 EA201891714A1 (ru) | 2019-02-28 |
| EA036542B1 EA036542B1 (ru) | 2020-11-20 |
| EA036542B9 true EA036542B9 (ru) | 2020-12-22 |
Family
ID=59563558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201891714A EA036542B9 (ru) | 2016-02-12 | 2017-02-10 | Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора |
Country Status (34)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3414241T (lt) | 2016-02-12 | 2022-08-25 | Astrazeneca Ab | Halogenu pakeisti piperidinai kaip oreksino receptoriaus moduliatoriai |
| EP3676261B1 (en) | 2017-09-01 | 2024-12-18 | Chronos Therapeutics Limited | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists |
| JP6874217B2 (ja) * | 2017-09-28 | 2021-05-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なｎ−（２，２−ジフルオロエチル）−ｎ−［（ピリミジニルアミノ）プロパニル］アリールカルボキサミド |
| US20210169883A1 (en) * | 2018-07-27 | 2021-06-10 | Icahn School Of Medicine At Mount Sinai | Method of treating aggression with orexin receptor antagonists |
| US12435076B2 (en) | 2019-11-01 | 2025-10-07 | Unimatec Co., Ltd. | Fluorine-containing pyrimidine compound and method for producing same |
| GB202311281D0 (en) | 2023-07-21 | 2023-09-06 | Bial Portela & Ca Sa | Orexin receptor antagonists |
| GB202311280D0 (en) | 2023-07-21 | 2023-09-06 | Bial Portela & Ca Sa | Orexin receptor antagonists |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013119639A1 (en) * | 2012-02-07 | 2013-08-15 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
| WO2013127913A1 (en) * | 2012-03-01 | 2013-09-06 | Rottapharm S.P.A. | 4,4-difluoro-piperidine-compounds |
| WO2015123355A1 (en) * | 2014-02-12 | 2015-08-20 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
Family Cites Families (157)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| US5049578A (en) | 1990-03-09 | 1991-09-17 | E. R. Squibb & Sons, Inc. | 1-aroyl or 1-acyl-2-2pyrrolidinyl-3,5-dihydroxy alkanoic and alkenoic acids, salts, esters and lactones |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| ATE391492T1 (de) | 1997-07-29 | 2008-04-15 | Alcon Lab Inc | Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat |
| WO1999038504A1 (en) | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| CA2331735A1 (en) | 1998-05-08 | 1999-11-18 | Smithkline Beecham P.L.C. | Phenylurea and phenylthio urea derivatives |
| WO2000047576A1 (en) | 1999-02-12 | 2000-08-17 | Smithkline Beecham Plc | Cinnamide derivatives as orexin-1 receptors antagonists |
| US6699879B1 (en) | 1999-02-12 | 2004-03-02 | Smithkline Beecham P.L.C. | Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists |
| JP2002536447A (ja) | 1999-02-12 | 2002-10-29 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | フェニル尿素およびフェニルチオ尿素誘導体 |
| AU5283800A (en) | 1999-05-24 | 2000-12-12 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| CA2408343A1 (en) | 2000-05-11 | 2002-11-07 | Banyu Pharmaceutical Co., Ltd. | N-acyltetrahydroisoquinoline derivatives |
| AU2001272476A1 (en) | 2000-06-16 | 2001-12-24 | Smithkline Beecham Plc | Piperidines for use as orexin receptor antagonists |
| EP1353918B1 (en) | 2000-11-28 | 2005-01-12 | Smithkline Beecham Plc | Morpholine derivatives as antagonists of orexin receptors |
| WO2002051232A2 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
| CZ20032990A3 (cs) | 2001-05-05 | 2004-04-14 | Smithkline Beecham P. L. C. | N-aroylové cyklické aminy |
| WO2002089800A2 (en) | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
| GB0126292D0 (en) | 2001-11-01 | 2002-01-02 | Smithkline Beecham Plc | Compounds |
| GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
| GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130341D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| MXPA04002269A (es) | 2002-07-09 | 2004-06-29 | Actelion Pharmaceuticals Ltd | Derivados de 7,8,9,10-tetrahidro-6h-azepino,6,7,8,9-tetrahidro-pirido y 2,3-dihidro-2h-pirrolo[2,1-b]-quinazolinona. |
| WO2004026866A1 (en) | 2002-09-18 | 2004-04-01 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
| BR0315115A (pt) | 2002-10-11 | 2005-08-16 | Actelion Pharmaceuticals Ltd | Compostos, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios em que se requer um antagonista de receptores de orexina humana, processo para a fabricação de composições farmacêuticas, e, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos |
| GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| WO2004052876A1 (en) | 2002-12-12 | 2004-06-24 | Janssen Pharmaceutica, N.V. | Substituted 4-phenyl-[1,3]-dioxanes |
| AU2004224156B2 (en) | 2003-03-26 | 2010-08-12 | Actelion Pharmaceuticals Ltd. | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists |
| ES2297413T3 (es) | 2003-04-28 | 2008-05-01 | Actelion Pharmaceuticals Ltd. | Derivados de quinoxalinona-3-ona utilizados como antagonistas del receptor de orexina. |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| DE602004023516D1 (de) | 2003-08-07 | 2009-11-19 | Allergan Inc | Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| HUP0304101A3 (en) | 2003-12-22 | 2008-10-28 | Sanofi Aventis | Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
| HUP0400405A3 (en) | 2004-02-10 | 2009-03-30 | Sanofi Synthelabo | Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
| JP4094050B2 (ja) | 2004-03-01 | 2008-06-04 | アクテリオン ファーマシューティカルズ リミテッド | 置換１，２，３，４−テトラヒドロイソキノリン誘導体 |
| WO2006067224A2 (en) | 2004-12-23 | 2006-06-29 | Biovitrum Ab (Publ) | Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists |
| AU2006235302A1 (en) | 2005-04-12 | 2006-10-19 | Merck & Co., Inc. | Amidopropoxyphenyl orexin receptor antagonists |
| US7968289B2 (en) | 2005-05-03 | 2011-06-28 | Ensemble Therapeutics Corporation | Turn over probes and use thereof for nucleic acid detection |
| EP1888563A1 (en) | 2005-05-23 | 2008-02-20 | Merck & Co., Inc. | Proline bis-amide orexin receptor antagonists |
| CA2617324A1 (en) | 2005-08-04 | 2007-02-15 | Merck & Co., Inc. | Aminoethane sulfonamide orexin receptor antagonists |
| US20090176789A1 (en) | 2005-08-26 | 2009-07-09 | Breslin Michael J | Diazaspirodecane orexin receptor antagonists |
| CA2629192A1 (en) | 2005-11-22 | 2007-05-31 | Merck & Co., Inc. | Indole orexin receptor antagonists |
| CN101009515A (zh) | 2006-01-24 | 2007-08-01 | 华为技术有限公司 | 通信终端设备管理方法及通信终端 |
| TW200800020A (en) | 2006-01-26 | 2008-01-01 | Basf Ag | Methods to use 3-pyridyl derivatives as pesticides |
| FR2896798A1 (fr) | 2006-01-27 | 2007-08-03 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| FR2896799B1 (fr) | 2006-02-02 | 2008-03-28 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| US20090105318A1 (en) | 2006-03-29 | 2009-04-23 | Coleman Paul J | Amidoethylthioether Orexin Receptor Antagonists |
| CN101460453B (zh) | 2006-04-11 | 2012-10-03 | 埃科特莱茵药品有限公司 | 磺酰胺化合物 |
| ATE496051T1 (de) | 2006-04-26 | 2011-02-15 | Actelion Pharmaceuticals Ltd | Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten |
| WO2007143813A1 (en) | 2006-06-16 | 2007-12-21 | Husky Injection Molding Systems Ltd. | Preventative maintenance update system |
| EP2049110B1 (en) | 2006-07-14 | 2014-08-20 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
| CA2657552A1 (en) | 2006-07-14 | 2008-01-17 | Merck & Co., Inc. | Substituted diazepan orexin receptor antagonists |
| AU2007272795A1 (en) | 2006-07-14 | 2008-01-17 | Merck & Co., Inc. | 2-substituted proline bis-amide orexin receptor antagonists |
| CA2659299A1 (en) | 2006-08-15 | 2008-02-21 | Actelion Pharmaceuticals Ltd | Azetidine compounds |
| WO2008026149A1 (en) | 2006-08-28 | 2008-03-06 | Actelion Pharmaceuticals Ltd | 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists |
| CL2007002809A1 (es) | 2006-09-29 | 2008-04-18 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas |
| US8133901B2 (en) | 2006-12-01 | 2012-03-13 | Actelion Pharmaceuticals Ltd. | 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| ES2380391T3 (es) | 2006-12-22 | 2012-05-11 | Actelion Pharmaceuticals Ltd. | Derivados de 5,6,7,8-tetrahidro-imidazo[1,5-a]pirazina |
| TW200833328A (en) | 2006-12-28 | 2008-08-16 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.1.0]hexane derivatives |
| WO2008087611A2 (en) | 2007-01-19 | 2008-07-24 | Actelion Pharmaceuticals Ltd | Pyrrolidine- and piperidine- bis-amide derivatives |
| EP2131654A4 (en) | 2007-03-02 | 2011-02-02 | Merck Sharp & Dohme | Bipyridine-carboxamide-orexin receptor Antagonist |
| AU2008223916A1 (en) | 2007-03-05 | 2008-09-12 | F. Hoffmann-La Roche Ag | Aminoamides as orexin antagonists |
| DE602008006368D1 (de) | 2007-03-15 | 2011-06-01 | Hoffmann La Roche | Malonamide als orexin-antagonisten |
| CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| ES2365444T3 (es) | 2007-04-04 | 2011-10-05 | F. Hoffmann-La Roche Ag | Heterociclos como antagonistas de orexina. |
| ES2351079T3 (es) | 2007-05-14 | 2011-01-31 | Actelion Pharmaceuticals Ltd. | Derivados de 2-ciclopropil-tiazol. |
| JP2010527924A (ja) | 2007-05-18 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト |
| US8030495B2 (en) | 2007-05-23 | 2011-10-04 | Coleman Paul J | Cyclopropyl pyrrolidine orexin receptor antagonists |
| WO2008147518A1 (en) | 2007-05-23 | 2008-12-04 | Merck & Co., Inc. | Pyridyl piperidine orexin receptor antagonists |
| JP2010531871A (ja) | 2007-07-03 | 2010-09-30 | アクテリオン ファーマシューティカルズ リミテッド | ３−アザ−ビシクロ［３．３．０］オクタン化合物 |
| KR20100046047A (ko) | 2007-07-27 | 2010-05-04 | 액테리온 파마슈티칼 리미티드 | 2-아자-비시클로[3.3.0]옥탄 유도체 |
| EP2185512B1 (en) | 2007-07-27 | 2010-12-29 | Actelion Pharmaceuticals Ltd. | Trans-3-aza-bicyclo[3.1.0]hexane derivatives |
| WO2009016087A1 (en) | 2007-08-02 | 2009-02-05 | F. Hoffmann-La Roche Ag | Monoamide derivatives as orexin receptor antagonists |
| CA2695621A1 (en) | 2007-08-09 | 2009-02-12 | Merck Sharp & Dohme Corp. | Pyridine carboxamide orexin receptor antagonists |
| BRPI0814149A2 (pt) | 2007-08-10 | 2011-09-13 | Cortex Pharma Inc | composto, composição farmacêutica, métodos de tratamento e uso do composto |
| BRPI0815079A2 (pt) | 2007-08-15 | 2015-02-03 | Actelion Pharmaceuticals Ltd | Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto |
| CA2699328A1 (en) | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
| JP2011502146A (ja) | 2007-10-29 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 置換ジアゼパンオレキシン受容体アンタゴニスト |
| WO2009079637A1 (en) | 2007-12-18 | 2009-06-25 | Concert Pharmaceuticals, Inc. | Tetrahydroisoquinoline derivatives |
| CA2705411A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Heteroaryl derivatives as orexin receptor antagonists |
| CA2709050C (en) | 2008-01-21 | 2016-06-14 | F. Hoffmann-La Roche Ag | Sulfonamides as orexin antagonists |
| ES2367341T3 (es) | 2008-02-12 | 2011-11-02 | F. Hoffmann-La Roche Ag | Derivados de piperidina-sulfonamida. |
| BRPI0908096A2 (pt) | 2008-02-21 | 2015-08-25 | Actelion Pharmaceuticals Ltd | Derivado de 2-aza-biciclo [2.2.1] heptano |
| GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
| JP2011522878A (ja) | 2008-06-11 | 2011-08-04 | アクテリオン ファーマシューティカルズ リミテッド | オレキシン受容体拮抗薬としてのテトラゾール化合物 |
| WO2009153180A1 (en) | 2008-06-16 | 2009-12-23 | F. Hoffmann-La Roche Ag | Heteroaromatic monoamides as orexinin receptor antagonists |
| US20110105514A1 (en) | 2008-06-25 | 2011-05-05 | Hamed Aissaoui | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds |
| CA2729985A1 (en) | 2008-07-07 | 2010-01-14 | Actelion Pharmaceuticals Ltd | Thiazolidine compounds as orexin receptor antagonists |
| CA2731403C (en) | 2008-07-29 | 2013-11-05 | F. Hoffmann-La Roche Ag | Pyrrolidin-3-ylmethyl-amine as orexin antagonists |
| AR072899A1 (es) | 2008-08-07 | 2010-09-29 | Merck Sharp & Dohme | Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad. |
| EP2161266A1 (en) | 2008-08-22 | 2010-03-10 | EVOTEC Neurosciences GmbH | Benzofuran derivatives as orexin receptor antagonists |
| WO2010044054A1 (en) | 2008-10-14 | 2010-04-22 | Actelion Pharmaceuticals Ltd | Phenethylamide derivatives and their heterocyclic analogues |
| WO2010048016A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,3-disubstituted piperidine orexin receptor antagonists |
| JP2012506375A (ja) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト |
| CA2739927A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | Disubstituted azepan orexin receptor antagonists |
| AU2009307916A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted morpholine orexin receptor antagonists |
| AU2009307918A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,4-disubstituted pyrrolidine orexin receptor antagonists |
| CA2739915A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| CA2741648A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
| WO2010051238A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Pyridazine carboxamide orexin receptor antagonists |
| EP2350010B1 (en) | 2008-10-30 | 2014-03-26 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
| EP2358712A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| EP2358713A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Imidazopyridazine derivatives acting as orexin antagonists |
| JP2012509910A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
| CA2745433A1 (en) | 2008-12-02 | 2010-06-10 | Glaxo Group Ltd. | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
| TW201031407A (en) | 2008-12-02 | 2010-09-01 | Glaxo Group Ltd | Novel compounds |
| JP2010155827A (ja) | 2008-12-04 | 2010-07-15 | Takeda Chem Ind Ltd | スピロ環化合物 |
| GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| US20100222396A1 (en) | 2009-01-30 | 2010-09-02 | Novartis Ag | 4-aryl-butane-1,3-diamides |
| US20120040991A1 (en) | 2009-04-24 | 2012-02-16 | Glaxo Group Limited | 3-azabicyclo [4.1.0] heptanes used as orexin antagonists |
| US20120101106A1 (en) | 2009-07-09 | 2012-04-26 | Mercer Swati P | Tetrahydronapthyridine Orexin Receptor Antagonists |
| EP2275421A1 (en) | 2009-07-15 | 2011-01-19 | Rottapharm S.p.A. | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction |
| US8809380B2 (en) | 2009-08-04 | 2014-08-19 | Raqualia Pharma Inc. | Picolinamide derivatives as TTX-S blockers |
| WO2011023585A1 (en) | 2009-08-24 | 2011-03-03 | Glaxo Group Limited | Piperidine derivatives used as orexin antagonists |
| US20120149723A1 (en) | 2009-08-24 | 2012-06-14 | Romano Di Fabio | 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder |
| ES2585806T3 (es) | 2009-10-23 | 2016-10-10 | Janssen Pharmaceutica N.V. | Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina |
| EP2491034B1 (en) | 2009-10-23 | 2013-12-18 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds as orexin receptor modulators |
| WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| WO2011053522A1 (en) | 2009-10-29 | 2011-05-05 | Merck Sharp & Dohme Corp. | Tertiary amide orexin receptor antagonists |
| US20120258957A1 (en) | 2009-11-23 | 2012-10-11 | Matilda Jane Bingham | Heterocyclic derivatives |
| WO2011073316A1 (en) | 2009-12-18 | 2011-06-23 | Novartis Ag | 4-aryl-butane-1,3-diamides |
| EP2516439B1 (en) | 2009-12-21 | 2014-01-22 | Novartis AG | Diaza-spiro[5.5]undecanes as orexin receptor antagonists |
| EP2516437B1 (en) | 2009-12-21 | 2014-01-29 | Novartis AG | Disubstituted heteroaryl-fused pyridines |
| WO2011138266A1 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indolizine and imidazopyridine derivatives as orexin receptor antagonists |
| WO2011138265A2 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indole and indazole derivatives as orexin receptor antagonists |
| US20130281465A1 (en) | 2010-12-17 | 2013-10-24 | Taisho Pharmaceutical Co., Ltd. | Pyrazole derivative |
| WO2012085852A1 (en) | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides |
| US20120165339A1 (en) | 2010-12-22 | 2012-06-28 | Eisai R&D Management Co., Ltd. | Cyclopropane derivatives |
| US20120165331A1 (en) | 2010-12-22 | 2012-06-28 | Sangamesh Badiger | Di/tri-aza-spiro-C9-C11alkanes |
| WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
| WO2012089607A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors |
| EP2484674A1 (en) | 2011-02-02 | 2012-08-08 | Rottapharm S.P.A. | Spiro aminic compounds with NK1 antagonist activity |
| WO2012110986A1 (en) | 2011-02-18 | 2012-08-23 | Actelion Pharmaceuticals Ltd | Novel pyrazole and imidazole derivatives useful as orexin antagonists |
| WO2012114252A1 (en) | 2011-02-21 | 2012-08-30 | Actelion Pharmaceuticals Ltd | Novel indole and pyrrolopyridine amides |
| WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
| EP2708537A4 (en) | 2011-05-10 | 2014-10-01 | Taisho Pharmaceutical Co Ltd | HETEROAROMATIC RING DERIVATIVE |
| JPWO2013005755A1 (ja) | 2011-07-05 | 2015-02-23 | 大正製薬株式会社 | メチルピペリジン誘導体 |
| WO2013050938A1 (en) | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| WO2013059163A1 (en) | 2011-10-21 | 2013-04-25 | Merck Sharp & Dohme Corp. | 2,5-disubstituted thiomorpholine orexin receptor antagonists |
| WO2013062857A1 (en) | 2011-10-25 | 2013-05-02 | Merck Sharp & Dohme Corp. | Piperidinyl alkyne orexin receptor antagonists |
| WO2013062858A1 (en) | 2011-10-25 | 2013-05-02 | Merck Sharp & Dohme Corp. | Isoxazolopyridine orexin receptor antagonists |
| DK2776430T3 (en) | 2011-11-08 | 2016-05-09 | Actelion Pharmaceuticals Ltd | 2- (1,2,3-triazol-2-yl) benzamide and 3- (1,2,3-triazol-2-yl) PICOLINAMIDDERIVATER AS orexin receptor antagonists |
| ITMI20112329A1 (it) | 2011-12-21 | 2013-06-22 | Rottapharm Spa | Nuovi derivati spiro amminici |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| WO2013123240A1 (en) | 2012-02-17 | 2013-08-22 | Eisai R&D Management Co., Ltd | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists |
| ITMI20120424A1 (it) | 2012-03-19 | 2013-09-20 | Rottapharm Spa | Composti chimici |
| TW201613902A (en) | 2014-08-13 | 2016-04-16 | Eolas Therapeutics Inc | Difluoropyrrolidines as orexin receptor modulators |
| LT3414241T (lt) * | 2016-02-12 | 2022-08-25 | Astrazeneca Ab | Halogenu pakeisti piperidinai kaip oreksino receptoriaus moduliatoriai |
-
2017
- 2017-02-10 LT LTEPPCT/US2017/017408T patent/LT3414241T/lt unknown
- 2017-02-10 MX MX2018009656A patent/MX2018009656A/es unknown
- 2017-02-10 AU AU2017217931A patent/AU2017217931B2/en active Active
- 2017-02-10 MY MYPI2018702747A patent/MY195239A/en unknown
- 2017-02-10 EA EA201891714A patent/EA036542B9/ru active IP Right Revival
- 2017-02-10 KR KR1020187025645A patent/KR102738491B1/ko active Active
- 2017-02-10 SM SM20220323T patent/SMT202200323T1/it unknown
- 2017-02-10 RS RS20220714A patent/RS63471B1/sr unknown
- 2017-02-10 US US16/076,818 patent/US10894789B2/en active Active
- 2017-02-10 DK DK17750847.0T patent/DK3414241T3/da active
- 2017-02-10 PT PT177508470T patent/PT3414241T/pt unknown
- 2017-02-10 JP JP2018542231A patent/JP6883045B2/ja active Active
- 2017-02-10 WO PCT/US2017/017408 patent/WO2017139603A1/en not_active Ceased
- 2017-02-10 PL PL17750847.0T patent/PL3414241T3/pl unknown
- 2017-02-10 SG SG11201806368VA patent/SG11201806368VA/en unknown
- 2017-02-10 CA CA3013927A patent/CA3013927C/en active Active
- 2017-02-10 CN CN201780022666.9A patent/CN109219606B/zh active Active
- 2017-02-10 HR HRP20220906TT patent/HRP20220906T1/hr unknown
- 2017-02-10 BR BR112018016446-1A patent/BR112018016446B1/pt active IP Right Grant
- 2017-02-10 ES ES17750847T patent/ES2923790T3/es active Active
- 2017-02-10 TN TNP/2018/000280A patent/TN2018000280A1/en unknown
- 2017-02-10 EP EP17750847.0A patent/EP3414241B1/en active Active
- 2017-02-10 CR CR20180429A patent/CR20180429A/es unknown
- 2017-02-10 HU HUE17750847A patent/HUE059280T2/hu unknown
- 2017-02-10 SI SI201731191T patent/SI3414241T1/sl unknown
- 2017-02-10 TW TW106104428A patent/TWI710557B/zh active
-
2018
- 2018-07-26 IL IL260788A patent/IL260788B/en unknown
- 2018-08-06 DO DO2018000179A patent/DOP2018000179A/es unknown
- 2018-08-07 CL CL2018002121A patent/CL2018002121A1/es unknown
- 2018-08-07 SV SV2018005731A patent/SV2018005731A/es unknown
- 2018-08-10 PH PH12018501708A patent/PH12018501708A1/en unknown
- 2018-08-30 ZA ZA2018/05839A patent/ZA201805839B/en unknown
- 2018-09-04 CO CONC2018/0009290A patent/CO2018009290A2/es unknown
-
2020
- 2020-12-09 US US17/116,773 patent/US11434236B2/en active Active
-
2022
- 2022-07-20 US US17/868,856 patent/US12084437B2/en active Active
- 2022-07-28 CY CY20221100519T patent/CY1125461T1/el unknown
-
2024
- 2024-08-07 US US18/797,152 patent/US20240400550A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013119639A1 (en) * | 2012-02-07 | 2013-08-15 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
| WO2013127913A1 (en) * | 2012-03-01 | 2013-09-06 | Rottapharm S.P.A. | 4,4-difluoro-piperidine-compounds |
| WO2015123355A1 (en) * | 2014-02-12 | 2015-08-20 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
Non-Patent Citations (1)
| Title |
|---|
| Jiang, R. et al., "Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists", Bioorganic & Medicinal Chemistry Letters, 2012, Vol. 22, pages 3890-3894. Page 3890, Abstract, page 3892 left column lines 16-19, Tables 1-5 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202109164B (en) | 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors | |
| EA033544B1 (ru) | Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret) | |
| BR112015019720B8 (pt) | Inibidores de (benzil-ciano-metil)-amidas de ácido 2-azabiciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c e composição farmacêutica | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| MX2017010477A (es) | Compuestos triciclicos y usos de los mismos en medicina. | |
| IN2015DN01815A (enExample) | ||
| MY194850A (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
| PH12014502341A1 (en) | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments | |
| MX2013008431A (es) | Antagonista del receptor de mineralocorticoides. | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| SG10201908582TA (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| MY201535A (en) | Therapeutic compounds | |
| PH12016501483A1 (en) | P-substituted asymmetric ureas and medical uses thereof | |
| MX2019006942A (es) | Agonistas de receptores de oxitocina no peptidicos. | |
| MY195239A (en) | Halo-Substituted Piperidines as Orexin Receptor Modulators | |
| MX371102B (es) | Nuevos derivados de bencimidazol como agentes antihistaminicos. | |
| AR088204A1 (es) | Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina | |
| PH12016501625A1 (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
| PH12021550549A1 (en) | Dp antagonist | |
| MY206632A (en) | Pyridopyrimidines as histamine h4-receptor inhibitors | |
| WO2013181217A3 (en) | Novel compounds and compositions for treatment of breathing control disorders or diseases | |
| MX2011008857A (es) | Derivados de oxiindol con actividad agonistica del receptor de motilina. | |
| MX2014006827A (es) | Derivados del acido cicloalcanocraboxilico como antagonistas del receptor cxcr3. | |
| MX2014000870A (es) | Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina. | |
| BR112014010719A2 (pt) | moduladores não competitivos de receptor nicotínico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Publication of the corrected specification to eurasian patent | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |
|
| NF4A | Restoration of lapsed right to a eurasian patent |
Designated state(s): BY KZ RU |